Congratulations to Daniel Jackson, MD for receiving funding for a consortium led by Children’s Hospital of Boston. The group will initiate an asthma prevention study entitled, “Controlling and Preventing Asthma Severity in Kids” (CASK). The study will determine whether omalizumab (anti-IgE) therapy given to 2- and 3-year-old children at high risk for asthma based upon having allergies and wheezing will prevent the progression to childhood asthma. This 7-year, U01 grant funded by the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID), includes a subcontract to UW-Madison totaling over $2 million.